Obesity and body weight control

Natural product therapy for body weight control, energy homeostasis and TIIDM: Emodin, isolated from Rhubarb,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 1/November/2017,11.56 pm
Natural product therapy for body weight control, energy homeostasis and TIIDM: Emodin, isolated from Rhubarb,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 1/November/2017,11.56 pm 960 720

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM:  Chenodeoxycholic acid (CDCA) [Trade name: Ursodiol] decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 25/October/2017, 12.01 am
Molecular therapy for body weight control, energy homeostasis and TIIDM:  Chenodeoxycholic acid (CDCA) [Trade name: Ursodiol] decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 25/October/2017, 12.01 am 960 720

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more

Natural product-based combinatorial therapy for body weight control, energy homeostasis and TIIDM: A therapeutic mix encompassing  Mangiferin, EGCG and Scopolin (MES)  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 20/October/2017,12.38 am
Natural product-based combinatorial therapy for body weight control, energy homeostasis and TIIDM: A therapeutic mix encompassing  Mangiferin, EGCG and Scopolin (MES)  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 20/October/2017,12.38 am 960 720

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Natural product therapy for body weight control, energy homeostasis and TIIDM: A therapeutic mix encompassing Berberine, Leucine and Genistein (BLG) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 10/October/2017,11.35 pm
Natural product therapy for body weight control, energy homeostasis and TIIDM: A therapeutic mix encompassing Berberine, Leucine and Genistein (BLG) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 10/October/2017,11.35 pm 960 720

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Milnacipran, a serotonin norepinephrine reuptake inhibitor,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 4/October/2017, 2.39 am
Molecular therapy for TIIDM and obesity-associated metabolic deficits: Milnacipran, a serotonin norepinephrine reuptake inhibitor,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 4/October/2017, 2.39 am 960 720

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more

Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: Teasaponin, isolated from camellia sinesis, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 27/September/2017, 1.24 am
Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: Teasaponin, isolated from camellia sinesis, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 27/September/2017, 1.24 am 960 720

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more
Start Typing